Cutaneous melanoma in patients treated with tumour necrosis factor inhibitors: a retrospective series of 15 patients

Authors

  • C. Chabbert,

    1. Department of Dermatology, University Hospital of Rennes, Rennes, France
    Search for more papers by this author
  • H. Adamski,

    Corresponding author
    1. Department of Dermatology, University Hospital of Rennes, Rennes, France
    Search for more papers by this author
    • BIOtherapy and Research in DERMatology’ (BIORDERM) clinical research network of the French ‘Grand Ouest’ regional area, Grand Ouest, France.
  • G. Guillet,

    1. Department of Dermatology, University Hospital of Poitiers, Poitiers, France
    Search for more papers by this author
    • BIOtherapy and Research in DERMatology’ (BIORDERM) clinical research network of the French ‘Grand Ouest’ regional area, Grand Ouest, France.
  • B. Sassolas,

    1. Department of Internal Medicine and Pneumology, University Hospital of Brest, Brest, France
    Search for more papers by this author
    • BIOtherapy and Research in DERMatology’ (BIORDERM) clinical research network of the French ‘Grand Ouest’ regional area, Grand Ouest, France.
  • L. Misery,

    1. Department of Dermatology, University Hospital of Brest, Brest, France
    Search for more papers by this author
    • BIOtherapy and Research in DERMatology’ (BIORDERM) clinical research network of the French ‘Grand Ouest’ regional area, Grand Ouest, France.
  • A. Perrinaud,

    1. Department of Dermatology, University Hospital of Tours, Tours, France
    Search for more papers by this author
  • L. Machet,

    1. Department of Dermatology, University Hospital of Tours, Tours, France
    Search for more papers by this author
    • BIOtherapy and Research in DERMatology’ (BIORDERM) clinical research network of the French ‘Grand Ouest’ regional area, Grand Ouest, France.
  • G. Quereux,

    1. Department of Dermatology, University Hospital of Nantes, Nantes, France
    Search for more papers by this author
    • BIOtherapy and Research in DERMatology’ (BIORDERM) clinical research network of the French ‘Grand Ouest’ regional area, Grand Ouest, France.
  • E. Esteve,

    1. Porte-Madeleine Hospital of Orléans, Cedex, France
    Search for more papers by this author
    • BIOtherapy and Research in DERMatology’ (BIORDERM) clinical research network of the French ‘Grand Ouest’ regional area, Grand Ouest, France.
  • E. Solau-Gervais,

    1. Department of Rheumatology, University Hospital of Poitiers, Poitiers, France
    Search for more papers by this author
  • A. Saraux,

    1. Department of Rheumatology, University Hospital of Brest, Brest, France
    Search for more papers by this author
  • E. Polard,

    1. Pharmacovigilance Center, University Hospital of Rennes, Rennes, France
    Search for more papers by this author
  • T. Lesimple,

    1. Oncology Center (Centre Régional de Lutte contre le Cancer) of Rennes, Rennes, France
    Search for more papers by this author
    • BIOtherapy and Research in DERMatology’ (BIORDERM) clinical research network of the French ‘Grand Ouest’ regional area, Grand Ouest, France.
  • F. Le Gall,

    1. Department of Pathology, University Hospital of Rennes, Rennes, France
    Search for more papers by this author
  • B. Dreno,

    1. Department of Dermatology, University Hospital of Nantes, Nantes, France
    Search for more papers by this author
    • BIOtherapy and Research in DERMatology’ (BIORDERM) clinical research network of the French ‘Grand Ouest’ regional area, Grand Ouest, France.
  • A. Dupuy

    1. Department of Dermatology, University Hospital of Rennes, Rennes, France
    Search for more papers by this author
    • BIOtherapy and Research in DERMatology’ (BIORDERM) clinical research network of the French ‘Grand Ouest’ regional area, Grand Ouest, France.

  • Conflicts of interest

    • Drs L. Misery, E. Solau-Gervais, A. Saraux and A. Dupuy have acted as Investigator, Speaker or in another capacity from the following companies: Abbvie, MSD and/or Pfizer.
  • Funding source

    • None declared.

Abstract

Background

Several case reports suggested that tumour necrosis factor-α (TNF) inhibitors might increase the incidence and/or alter the natural course of melanoma towards a more aggressive behaviour.

Objective

Our objective was to point if history of melanoma in patients exposed to TNF inhibitors could present with a particular pattern at diagnosis or during follow-up.

Methods

We performed a retrospective multicentre study settled in the West part of France to collect and analyse all cases of patients with melanoma who received anti-TNF therapy.

Results

Fifteen cases were included. First, 10 patients (mean age: 55.6 years; sex ratio: 1) had a melanoma diagnosed after TNF inhibitors initiation. The mean duration between initiation of treatment and melanoma was 48.7 months. Two patients died of metastatic disease. Second, four patients had a past history of melanoma before anti-TNF therapy (mean duration of treatment: 10.8 months). None experienced a progression of melanoma disease. Last, one woman had a past history of melanoma before and then developed a second melanoma when exposed to biotherapy.

Conclusion

Our case series does not reveal a distinct profile of melanoma in the patients exposed to TNF inhibitors. Additional prospective trials including larger number of patient are needed to demonstrate the possible link between biological therapy with TNF inhibitors and development of melanoma.

Ancillary